SCHEMBL20280938

SCHEMBL20280938

COc1cc2nc(-c3cccc4cccnc34)nc(NCCNS(=O)(=O)c3ccccc3)c2cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLRA3 O75311 2/20 0.49
GLRB P48167 1/20 0.49
ALDH1A1 P00352 4/20 0.49
GAA P10253 1/20 0.49
HMOX1 P09601 2/20 0.46
SLC40A1 Q9NP59 5/20 0.46
GBA1 P04062 1/20 0.45
TDP1 Q9NUW8 3/20 0.43
KDM4E B2RXH2 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2D6 P10635 2/20 0.43
ALOX15 P16050 2/20 0.43
PDE5A O76074 1/20 0.43
PKM P14618 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
USP2 O75604 1/20 0.42
CYP3A4 P08684 1/20 0.42
HSD17B10 Q99714 1/20 0.42
LRRK2 Q5S007 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20280935 0.84 PDE4A (0.59) ALDH1A1GBA1TDP1KDM4ECYP1A2
SCHEMBL20266993 0.82 SYK (0.45) ALDH1A1TDP1KDM4ECYP1A2CYP2D6
SCHEMBL20281074 0.81 PGK1 (0.57) ALDH1A1GBA1TDP1KDM4ECYP1A2
SCHEMBL20280950 0.80 CYP1A2 (0.45) ALDH1A1TDP1KDM4ECYP1A2CYP2D6
SCHEMBL20280942 0.77 CYP1A2 (0.46) ALDH1A1TDP1KDM4ECYP1A2CYP2D6
SCHEMBL20280944 0.76 CYP1A2 (0.60) ALDH1A1GBA1TDP1KDM4ECYP1A2
SCHEMBL20281126 0.73 LATS1 (0.41) ALDH1A1TDP1KDM4ECYP1A2CYP2D6
SCHEMBL26203646 0.73 LATS1 (0.41) ALDH1A1TDP1KDM4ECYP1A2CYP2D6
SCHEMBL20266999 0.70 PDGFRB (0.43) ALDH1A1GAASLC40A1KMT2AAGTR1
SCHEMBL20267023 0.69 PDGFRB (0.46) KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718609-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-08-08 US disclosed
US-11718609-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-08-08 US disclosed
US-20210130338-A1 Heparanase Inhibitors and Use Thereof Beta Therapeutics Pty Ltd (AU) 2021-05-06 US disclosed
US-20200093852-A1 Methods of Treating Ocular Disorders Beta Therapeutics Pty Ltd (AU) 2020-03-26 US disclosed
WO-2018107200-A1 HEPARANASE INHIBITORS AND USE THEREOF Beta Therapeutics Pty Ltd (AU) 2018-06-21 WO disclosed
WO-2018107226-A1 METHODS OF TREATING OCULAR DISORDERS Beta Therapeutics Pty. Ltd. (AU) 2018-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200093852-A1 Methods of Treating Ocular Disorders ALDH1A2, HPSE, RB1 GLRA3 3937/4885GLRB 4075/4885ALDH1A1 2240/4885
US-20210130338-A1 Heparanase Inhibitors and Use Thereof HPSE, HEXD, ENGASE GLRA3 3109/4885GLRB 2594/4885ALDH1A1 2194/4885
US-11718609-B2 Heparanase inhibitors and use thereof HPSE, HEXD, ENGASE GLRA3 3109/4885GLRB 2594/4885ALDH1A1 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.